The B-Cell Chronic Lymphocytic Leukemia drugs in development market research report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for B-Cell Chronic Lymphocytic Leukemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued products.
GlobalData tracks 28 drugs in development for B-Cell Chronic Lymphocytic Leukemia by 26 companies/universities/institutes. The top development phase for B-Cell Chronic Lymphocytic Leukemia is phase i with ten drugs in that stage. The B-Cell Chronic Lymphocytic Leukemia pipeline has 20 drugs in development by companies and eight by universities/ institutes. Some of the companies in the B-Cell Chronic Lymphocytic Leukemia pipeline products market are: Bristol-Myers Squibb, CRISPR Therapeutics and Beijing Boren Hospital.
The key targets in the B-Cell Chronic Lymphocytic Leukemia pipeline products market include B Lymphocyte Antigen CD19, B Lymphocyte Antigen CD20, and Tyrosine Protein Kinase BTK.
The key mechanisms of action in the B-Cell Chronic Lymphocytic Leukemia pipeline product include Tyrosine Protein Kinase BTK Inhibitor with three drugs in Phase II. The B-Cell Chronic Lymphocytic Leukemia pipeline products include six routes of administration with the top ROA being Intravenous and four key molecule types in the B-Cell Chronic Lymphocytic Leukemia pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.
B-Cell Chronic Lymphocytic Leukemia overview
B-cell chronic lymphocytic leukemia is a type of slow-growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms, or in the groin; pain or discomfort under the ribs on the left side due to an enlarged spleen; frequent or repeated infections and slow healing, due to a lack of normal white blood cells; excessive sweating at night; and unintentional weight loss. Treatment includes chemotherapy and radiation.
For a complete picture of B-Cell Chronic Lymphocytic Leukemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
